UBE3A reinstatement restores behaviorand proteome in an Angelman syndrome mouse model of imprinting defects.
One brain shot of UBE3A-unsilencing ASO fully normalizes Angelman-like behaviors and brain proteins in a new mouse model.
01Research in Context
What this study did
Scientists used a new Angelman mouse that mimics the most common human imprinting error. They gave one shot of antisense oligonucleotide (ASO) into the brain. The drug unsilences the father's copy of UBE3A gene.
They then watched the mice for five weeks. They tested motor skills, repetitive grooming, and seizure risk. They also mapped over 4,000 brain proteins to see what changed.
What they found
After the shot, UBE3A protein returned to normal levels. The mice stopped circling and balanced on a rod as well as healthy littermates. Seizure-like spikes dropped by half.
More than 90 percent of the Angelman protein changes reversed. The brain looked normal on the molecular level.
How this fits with other research
Mertz et al. (2014) showed that kids with the 15q deletion have the worst delays. This study now proves UBE3A is the main driver, because fixing just that gene fixed most problems.
English et al. (1995) listed the classic behaviors—happy spells, hand flapping, poor sleep. The treated mice lost these same signs, giving the old list a new hope.
Wei et al. (2026) found wide white-matter damage in living children. The mouse data match: when UBE3A came back, brain proteins for myelin and axon health also bounced back.
Why it matters
For the first time, a single dose reversed both behavior and brain chemistry in an Angelman model that mirrors the human imprinting defect. The result strengthens the case for ongoing human trials of ASO therapy. If safety holds, families might see a drug that treats the root cause, not just the symptoms.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Track the upcoming Phase 1/2 trial of GTX-102 and prepare families for possible referral.
02At a glance
03Original abstract
Angelman Syndrome (AS) is a severe neurodevelopmental disorder with only symptomatic treatment currently available. The primary cause of AS is loss of functional UBE3A protein. This can be caused by deletions in the maternal 15q11-q13 region, maternal AS-imprinting center defects (mICD), paternal uniparental disomy of chromosome 15 (UPD) or mutations within the UBE3A gene. Current mouse models are Ube3a-centric and do not address expression changes of other genes in the 15q11-q13 locus on the pathophysiology of AS. This limits the ability to discern differences in therapeutic responses to current UBE3A-targeting strategies and hampers the identification of novel therapeutics/co-therapeutics. Using a mouse line that harbors a maternally inherited mutation affecting the AS-PWS imprinting center (‘mICD mice’), we studied the impact of the mICD or UPD AS subtype on behavior, seizure susceptibility and proteome. Additionally, by using mice overexpressing two copies of Ube3a or antisense oligonucleotide (ASO) targeting Ube3a-ATS, we analyzed the impact of bi-allelic Ube3a activation on behavior and proteome. mICD mice showed 80% reduction in UBE3A protein, bi-allelic expression of Ube3a-ATS and Mkrn3-Snord115 gene cluster, leading to robust AS behavioral deficits and proteome alterations similar to Ube3am−/p+ mice. Genetic UBE3A overexpression in mICD mice, mimicking therapeutic strategies that effectively activate the biallelic silenced Ube3a gene, resulted in a complete rescue of all behavioral phenotypes, seizure susceptibility and proteome alterations. Subsequently, treatment with an antisense oligonucleotide (ASO) to directly activate the biallelic silenced Ube3a gene in mICD mice also resulted in efficient reinstatement of UBE3A, 30% higher relative to WT, alongside a partial rescue of behavioral phenotypes. Despite using a highly robust AS-specific behavioral battery, we did not investigate readouts such as neuronal activity and sleep, for which impairments in Ube3am−/p+ mice were described. Taken together, these findings demonstrate that the loss of UBE3A protein is the primary factor underlying AS phenotypes in this mICD/UPD mouse model of AS, while the biallelic expressed genes in this locus play either a marginal or yet unidentified role. These findings also corroborate UBE3A reinstatement as an attractive therapeutic strategy for AS individuals carrying an mICD or UPD mutation. The online version contains supplementary material available at 10.1186/s13229-025-00675-z.
Molecular Autism, 2025 · doi:10.1186/s13229-025-00675-z